NCT00380224

Brief Summary

This study will compare bifeprunox to a currently marketed medication, Zyprexa (olanzapine), with respect to the affect on weight during the treatment of outpatients with schizophrenia. The study will compare the effect of these medications on several variables, including body weight and triglyceride levels.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P25-P50 for phase_3 schizophrenia

Timeline
Completed

Started Jul 2006

Shorter than P25 for phase_3 schizophrenia

Geographic Reach
1 country

67 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 21, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 25, 2006

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2007

Completed
Last Updated

December 27, 2007

Status Verified

December 1, 2007

First QC Date

September 21, 2006

Last Update Submit

December 18, 2007

Conditions

Keywords

schizophrenia

Outcome Measures

Primary Outcomes (1)

  • Change from baseline on body weight at the final evaluation.

Secondary Outcomes (1)

  • Change from baseline in triglyceride level; Change from baseline in waist circumference; and Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score.

Interventions

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Current treatment of at least 3 months with olanzapine.
  • Primary diagnosis of schizophrenia.
  • Total Positive and Negative Symptoms Scale (PANSS) score \<=70 at screening and baseline.

You may not qualify if:

  • Psychiatric diagnosis other than schizophrenia, as assessed by the modified Mini International Neuropsychiatric Interview (MINI), and considered by the investigator to be the primary psychiatric diagnosis.
  • History or presence of clinically significant cardiovascular, endocrine, hepatic, renal or other medical disease that might be detrimental to the subject or confound the study.
  • History of any suicide attempt within 3 years of day -1 or significant immediate risk of violence or suicidality.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (67)

Unknown Facility

Little Rock, Arkansas, 72201, United States

Location

Unknown Facility

Little Rock, Arkansas, 72211, United States

Location

Unknown Facility

Anaheim, California, 92802, United States

Location

Unknown Facility

Anaheim, California, 92804, United States

Location

Unknown Facility

Anaheim, California, 92805, United States

Location

Unknown Facility

Boynton Beach, California, 33426, United States

Location

Unknown Facility

Costa Mesa, California, 92363, United States

Location

Unknown Facility

Costa Mesa, California, 92627, United States

Location

Unknown Facility

Escondido, California, 92025, United States

Location

Unknown Facility

Garden Grove, California, 92845, United States

Location

Unknown Facility

Glendale, California, 91206, United States

Location

Unknown Facility

Huntington Beach, California, 92648, United States

Location

Unknown Facility

La Mesa, California, 91942, United States

Location

Unknown Facility

National City, California, 91950, United States

Location

Unknown Facility

Oceanside, California, 92056, United States

Location

Unknown Facility

Paramount, California, 90723, United States

Location

Unknown Facility

Rosemead, California, 91770, United States

Location

Unknown Facility

San Diego, California, 92108, United States

Location

Unknown Facility

San Diego, California, 92123, United States

Location

Unknown Facility

San Diego, California, 92126, United States

Location

Unknown Facility

Santa Ana, California, 92705, United States

Location

Unknown Facility

New Britain, Connecticut, 06050, United States

Location

Unknown Facility

New London, Connecticut, 06320, United States

Location

Unknown Facility

DeLand, Florida, 32720, United States

Location

Unknown Facility

Fort Lauderdale, Florida, 33319, United States

Location

Unknown Facility

Jacksonville, Florida, 32256, United States

Location

Unknown Facility

North Miami, Florida, 33161, United States

Location

Unknown Facility

St. Petersburg, Florida, 33711, United States

Location

Unknown Facility

Atlanta, Georgia, 30308, United States

Location

Unknown Facility

Augusta, Georgia, 30912, United States

Location

Unknown Facility

Marietta, Georgia, 30060, United States

Location

Unknown Facility

Coevr d'Alene, Idaho, 83814, United States

Location

Unknown Facility

Chicago, Illinois, 60631, United States

Location

Unknown Facility

Hoffman Estates, Illinois, 60194, United States

Location

Unknown Facility

Joliet, Illinois, 60077, United States

Location

Unknown Facility

Naperville, Illinois, 60540, United States

Location

Unknown Facility

Lake Charles, Louisiana, 70601, United States

Location

Unknown Facility

Gaithersburg, Maryland, 20877, United States

Location

Unknown Facility

Worcester, Massachusetts, 01605, United States

Location

Unknown Facility

Flowood, Mississippi, 39232, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

St Louis, Missouri, 63118, United States

Location

Unknown Facility

St Louis, Missouri, 63128, United States

Location

Unknown Facility

North Platte, Nebraska, 69101, United States

Location

Unknown Facility

Cherry Hill, New Jersey, 08002, United States

Location

Unknown Facility

Clementon, New Jersey, 08021, United States

Location

Unknown Facility

New York, New York, 10035, United States

Location

Unknown Facility

Rochester, New York, 14624, United States

Location

Unknown Facility

Staten Island, New York, 10312, United States

Location

Unknown Facility

Butner, North Carolina, 27509, United States

Location

Unknown Facility

Chapel Hill, North Carolina, 27599, United States

Location

Unknown Facility

Durham, North Carolina, 27707, United States

Location

Unknown Facility

Morehead City, North Carolina, 28557, United States

Location

Unknown Facility

Fargo, North Dakota, 58102, United States

Location

Unknown Facility

Cleveland, Ohio, 44109, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73118, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73139, United States

Location

Unknown Facility

Norristown, Pennsylvania, 19401, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19149, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15108, United States

Location

Unknown Facility

Cordova, Tennessee, 38018, United States

Location

Unknown Facility

Memphis, Tennessee, 38105, United States

Location

Unknown Facility

Murfressboro, Tennessee, 37129, United States

Location

Unknown Facility

Nashville, Tennessee, 37212, United States

Location

Unknown Facility

Austin, Texas, 78756, United States

Location

Unknown Facility

DeSoto, Texas, 75115, United States

Location

Unknown Facility

Irving, Texas, 75062, United States

Location

MeSH Terms

Conditions

Schizophrenia

Interventions

bifeprunoxOlanzapine

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 21, 2006

First Posted

September 25, 2006

Study Start

July 1, 2006

Study Completion

September 1, 2007

Last Updated

December 27, 2007

Record last verified: 2007-12

Locations